Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies. Founded by Prof. Dr. Eva van Rooij and Prof. Dr. Yigal Pinto in 2022, the company has made significant progress with Dr. Margien Boels, PhD, as Chief Operating Officer. 

In October last year, RegMed XB applied for a 3-year Public-Private Partnership (PPS) subsidy program, called 'Regenerative Medicine Translational Synergy'. 

As 2025 has started, we are sharing a look back with the RegMed XB Highlights 2024.